Document is current
Any future updates will be listed below
-
Authors
Yang, Tangpo https://orcid.org/0000-0002-4174-5709
Cuesta, Adolfo https://orcid.org/0000-0003-2389-5823
Wan, Xiaobo
Craven, Gregory B. https://orcid.org/0000-0003-3414-8348
Hirakawa, Brad
Khamphavong, Penney
May, Jeffrey R.
Kath, John C.
Lapek, John D. Jr.
Niessen, Sherry
Burlingame, Alma L. https://orcid.org/0000-0002-8403-7307
Carelli, Jordan D. https://orcid.org/0000-0001-7625-7505
Taunton, Jack https://orcid.org/0000-0002-9627-5898
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (F31CA214028)
Pfizer
- License Information
-
More Information
Article History
Received: 29 August 2021
Accepted: 23 March 2022
First Online: 19 May 2022
Competing interests
: T.Y., B.H., P.K., J.R.M., J.C.K., J.D.L., S.N. and J.D.C. are current or former employees of Pfizer. J.T. is a founder of Global Blood Therapeutics, Principia Biopharma, Kezar Life Sciences, Cedilla Therapeutics and Terremoto Biosciences, and is a scientific advisor to Entos.
